A groundbreaking AI-powered blood test is being trialled by the NHS, potentially transforming how postmenopausal women are screened for womb cancer. Currently, around 90,000 women annually undergo invasive transvaginal ultrasound scans due to concerns over heavy bleeding. This new test could spare about 18,000 of them from such procedures, as it boasts a 99% accuracy rate in detecting and ruling out gynaecological cancers.
Developed by Leeds-based PinPoint Data Science, the test analyses 30 blood markers to assess cancer risk. Its introduction could significantly reduce the number of unnecessary invasive tests, allowing healthcare providers to focus on patients who truly need immediate attention. This shift not only enhances patient comfort but also streamlines the diagnostic process, potentially alleviating pressures on NHS waiting lists.
GPs have noted the challenges in ruling out cancer, often requiring multiple consultations. The AI test promises to expedite this process, providing quicker peace of mind for patients. As hospitals begin to adopt this technology, it is expected to lead to earlier diagnoses and better outcomes for those who do have cancer.
While the initial trials show promise, further research is needed to fully understand the long-term benefits for both patients and the NHS. However, the potential to revolutionise cancer screening and reduce unnecessary procedures is a significant step forward in women’s health.
Source: The Guardian
